Idactamab

Cat. No.:	HY-P99654
CAS No.:	2245205-37-0
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5)[1][2].
IC_{50} & Target	ASCT2 (SLC1A5)[1]
In Vitro	Idactamab inhibits different heme cancer cell lines with IC_{50} of 0.05-65 ng/mL[1]. ASCT2 (SLC1A5) is a multi-pass, Na^+-dependent neutral amino acid transporter that mediates the uptake of amino acids required for tumor growth and progression[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Idactamab improves 3 disseminated Acute Myeloid Leukemia (AML) cell line models: The survival rates of TF1α (high expression of ASCT2), MOLM-13 (low expression of ASCT2) and M.V.411 (high expression of ASCT2) were 0.05 mg/kg, 0.1 mg/kg, and 0.1 mg/kg, respectively[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Pore N, et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological cancers[J]. Blood, 2018, 132: 4071.

[2]. Monks N R, et al. Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies[J]. Cancer Research, 2018, 78(13_Supplement): LB-295-LB-295.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA